4,811 Shares in Kenvue Inc. (NYSE:KVUE) Purchased by AlphaCore Capital LLC

AlphaCore Capital LLC purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,811 shares of the company’s stock, valued at approximately $115,000.

Other institutional investors have also made changes to their positions in the company. Pittenger & Anderson Inc. acquired a new stake in shares of Kenvue during the first quarter valued at about $30,000. TruNorth Capital Management LLC acquired a new stake in shares of Kenvue during the first quarter valued at about $36,000. Bank Julius Baer & Co. Ltd Zurich increased its position in shares of Kenvue by 120.6% during the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock valued at $41,000 after acquiring an additional 929 shares during the last quarter. Continuum Advisory LLC increased its position in shares of Kenvue by 2,071.1% during the first quarter. Continuum Advisory LLC now owns 1,954 shares of the company’s stock valued at $47,000 after acquiring an additional 1,864 shares during the last quarter. Finally, Clarity Asset Management Inc. acquired a new stake in shares of Kenvue during the fourth quarter valued at about $45,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Down 0.6%

Shares of Kenvue stock opened at $21.22 on Tuesday. Kenvue Inc. has a 52-week low of $19.75 and a 52-week high of $25.17. The company has a 50 day moving average of $21.57 and a 200 day moving average of $22.43. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $40.71 billion, a P/E ratio of 28.67, a P/E/G ratio of 4.08 and a beta of 0.83.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter in the previous year, the firm earned $0.32 earnings per share. The firm’s quarterly revenue was down 4.0% on a year-over-year basis. As a group, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th will be paid a $0.2075 dividend. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date is Wednesday, August 13th. Kenvue’s payout ratio is presently 110.81%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on KVUE shares. Citigroup dropped their price target on shares of Kenvue from $24.50 to $22.00 and set a “neutral” rating for the company in a research report on Tuesday, July 15th. Barclays lowered their price objective on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research note on Tuesday, July 15th. Royal Bank Of Canada lowered their price objective on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday. Bank of America lowered their price objective on shares of Kenvue from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, July 15th. Finally, Canaccord Genuity Group lowered their price objective on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research note on Friday. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Kenvue currently has an average rating of “Hold” and an average price target of $24.38.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.